This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Elanco Animal Health moves to dismiss US price-fixing claims

( October 25, 2024, 18:31 GMT | Official Statement) -- MLex Summary: Elanco Animal Health moved to dismiss US antitrust claims accusing it of illegally fixing the prices of branded Advantage II and K9 Advantix II squeeze-on, topical flea and tick prevention products, saying even if plaintiffs had standing, they’ve failed to show that the alleged vertical arrangements with retailers harm competition in a relevant market. “Plaintiff contends the market is limited to a single active ingredient, a single method of application, and a single type of distribution: topical flea and tick products for dogs and cats containing the active ingredient imidacloprid sold by five specific pet specialty stores in the US. That market definition is not plausible,” Elanco said. See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections